Compare Stocks → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:ADDXFNASDAQ:BPTHNASDAQ:JAGXNASDAQ:SVRANASDAQ:VVUS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADDXFAddex Therapeutics$0.99$0.99$0.99▼$0.99N/A0.25N/AN/ABPTHBio-Path$4.22+4.5%$7.00$3.51▼$44.80$2.87M0.6622,925 shs46,084 shsJAGXJaguar Health$0.09+28.6%$0.08$0.05▼$1.22$4.56M1.3138.87 million shs58.66 million shsSVRASavara$4.98+2.7%$4.94$1.63▼$5.70$687.99M0.77824,843 shs904,245 shsVVUSVIVUS$0.37$0.44▼$4.75$7.33M-0.841.44 million shs2.03 million shsElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADDXFAddex Therapeutics0.00%0.00%0.00%0.00%0.00%BPTHBio-Path+0.50%-9.42%-30.34%-58.69%-87.68%JAGXJaguar Health+5.65%-8.76%+21.50%-54.97%-90.65%SVRASavara-1.22%-0.82%-7.09%+0.62%+137.75%VVUSVIVUS0.00%0.00%0.00%0.00%0.00%A lot of people are making this costly mistake (Ad)You may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. Click here to jump in on the next oneMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADDXFAddex TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ABPTHBio-Path1.3717 of 5 stars3.52.00.00.02.30.00.6JAGXJaguar HealthN/AN/AN/AN/AN/AN/AN/AN/ASVRASavara1.9659 of 5 stars3.51.00.00.02.62.50.6VVUSVIVUSN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADDXFAddex TherapeuticsN/AN/AN/AN/ABPTHBio-Path3.00Buy$40.00847.87% UpsideJAGXJaguar HealthN/AN/AN/AN/ASVRASavara3.00Buy$8.2064.66% UpsideVVUSVIVUSN/AN/AN/AN/ACurrent Analyst RatingsLatest SVRA, VVUS, JAGX, BPTH, and ADDXF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2024BPTHBio-PathRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $40.003/4/2024SVRASavaraPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$7.00 ➝ $16.002/15/2024SVRASavaraJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$8.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADDXFAddex TherapeuticsN/AN/AN/AN/AN/AN/ABPTHBio-PathN/AN/AN/AN/A$0.71 per shareN/AJAGXJaguar Health$11.96M0.38N/AN/A($0.32) per share-0.28SVRASavaraN/AN/AN/AN/A$1.04 per shareN/AVVUSVIVUS$69.76M0.00N/AN/A($6.50) per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADDXFAddex TherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/ABPTHBio-Path-$16.08M-$40.80N/AN/AN/AN/A-375.74%-248.63%5/10/2024 (Estimated)JAGXJaguar Health-$47.45MN/A0.00N/AN/A-370.40%-1,191.67%-79.95%4/1/2024 (Confirmed)SVRASavara-$54.70M-$0.33N/AN/AN/AN/A-46.27%-35.94%5/20/2024 (Estimated)VVUSVIVUS-$31.50M-$2.96N/AN/AN/A-39.28%N/A-12.18%N/ALatest SVRA, VVUS, JAGX, BPTH, and ADDXF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024N/AJAGXJaguar HealthN/AN/AN/AN/AN/AN/A 3/8/202412/31/2023BPTHBio-Path-$5.40-$5.40N/AN/AN/AN/A 3/7/2024Q4 2023SVRASavara-$0.11-$0.09+$0.02-$0.09N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADDXFAddex TherapeuticsN/AN/AN/AN/AN/ABPTHBio-PathN/AN/AN/AN/AN/AJAGXJaguar HealthN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/AVVUSVIVUSN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADDXFAddex TherapeuticsN/AN/AN/ABPTHBio-PathN/A1.601.60JAGXJaguar Health22.001.771.10SVRASavara0.1915.6615.66VVUSVIVUSN/A0.430.28OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADDXFAddex TherapeuticsN/ABPTHBio-Path5.74%JAGXJaguar Health12.04%SVRASavara87.93%VVUSVIVUS7.32%Insider OwnershipCompanyInsider OwnershipADDXFAddex TherapeuticsN/ABPTHBio-Path3.05%JAGXJaguar Health0.16%SVRASavara4.58%VVUSVIVUS12.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADDXFAddex Therapeutics26N/AN/ANot OptionableBPTHBio-Path10680,000658,000OptionableJAGXJaguar Health6050.76 million50.68 millionNo DataSVRASavaraN/A138.15 million131.82 millionOptionableVVUSVIVUS5717.87 millionN/AOptionableSVRA, VVUS, JAGX, BPTH, and ADDXF HeadlinesSourceHeadlineVIVUS Provides Update on Pipeline and Program Milestonesmarkets.businessinsider.com - January 8 at 10:04 AMShark research group to build new global headquarters in Jacksonville with help from state fundingactionnewsjax.com - June 26 at 9:16 AMMetaview announces Answers, the world's first conversational AI for the interview processit.tmcnet.com - May 25 at 11:10 AMPancrelipase (CAS 53608-75-6) Market 2023 | Industry Growth ... - StreetBuzznews.google.com - May 12 at 2:58 AMExploring Huge Demand of Peripherally Acting Anti-Obesity Drug ... - Digital Journalnews.google.com - May 12 at 2:58 AMExtensive Growth Opportunities to be Witnessed by Prescription Weight-Loss Pills Market 2023 Analysis of Risin - openPRnews.google.com - May 11 at 8:54 AMErectile Dysfunction Drugs Market to Register High Demand Rate by ... - Cottonwood Holladay Journalnews.google.com - May 11 at 8:54 AMMilestone Pharmaceuticals Reports First Quarter 2023 Financial ... - PR Newswirenews.google.com - May 11 at 8:54 AMAnti-obesity Therapeutics Market to Witness the Highest Growth ... - Cottonwood Holladay Journalnews.google.com - May 11 at 3:54 AMAnti Obesity Drugs Market Future Industry Scope for New ... - Digital Journalnews.google.com - May 11 at 3:54 AMThis Crazy Six-Wheel Hatchback by Briggs & Stratton Was One of ... - autoevolutionnews.google.com - May 10 at 12:51 PMProstatic Artery Embolization Market Current and Upcoming Projects ... - Digital Journalnews.google.com - May 9 at 6:48 AMThis 1899 Porsche Pioneered Rivian's Quad-Motor Drive, Ram ... - MotorBiscuitnews.google.com - May 7 at 8:20 PMPorsche Pioneered the Range-Extended EV 100+ Years Before ... - MotorBiscuitnews.google.com - May 6 at 3:22 PMIncreasing Opportunities In Peripherally Acting Anti-Obesity Drug Market Latest Trends, Technological Advancem - openPRnews.google.com - May 5 at 1:45 PMNonalcoholic Steatohepatitis Treatment Market Outlook Growths ... - Digital Journalnews.google.com - May 5 at 7:44 AMA Big Fat Problem: Will children in the UK be given weight-loss injections? - Firstpostnews.google.com - May 2 at 10:24 AMIntraoperative Ultrasound Market Latest Trends, Techniques and Applications|2023-2030 - openPRnews.google.com - April 28 at 9:38 AMBuild Your Own Case Study | Obesity: Treating the Whole Patient - Healionews.google.com - April 27 at 8:14 PMBladder Cancer Market Demand in Various industries and Significant for Various Regions|2023-2030 - openPRnews.google.com - April 27 at 3:10 PMPediatric Obesity Management Market is projected to grow with a 4 ... - Future Market Insightsnews.google.com - April 27 at 10:10 AMGlobal Erectile Dysfunction Drugs Market Analysis by Recent Trends, Development, Regional Growth Overview and - openPRnews.google.com - April 26 at 7:33 AMNon-Alcoholic Steatohepatitis (NASH) Market Analysis, Trends, Growth, Research And Forecast 2032 - openPRnews.google.com - April 25 at 2:02 AMWhat to Know About Obesity and Bone Health - Health Centralnews.google.com - April 24 at 4:02 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAddex TherapeuticsOTCMKTS:ADDXFAddex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot-Marie-Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.Bio-PathNASDAQ:BPTHBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 (BP1002) for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 (BP1003) for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and BP1001-A for the treatment of solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.Jaguar HealthNASDAQ:JAGXJaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.SavaraNASDAQ:SVRASavara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.VIVUSNASDAQ:VVUSVIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.